Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 10/20 | 0.44 |
| ▸ | PRKDC | P78527 | 4/20 | 0.44 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629341 | 0.83 | IKBKB (0.46) | IKBKBATRPRKDCL3MBTL1 | |
| SCHEMBL11888377 | 0.73 | RAB9A (0.47) | CYP1A2L3MBTL1 | |
| SCHEMBL13859969 | 0.72 | PLA2G2A (0.47) | ATRPRKDCCYP3A4 | |
| SCHEMBL13629327 | 0.71 | PLA2G2A (0.45) | ATRPRKDCCYP1A2CYP3A4 | |
| SCHEMBL14136200 | 0.70 | SMN1; SMN2 (0.47) | CYP1A2L3MBTL1 | |
| SCHEMBL20899047 | 0.70 | LDHA (0.50) | IKBKBATRPRKDCMAP2K3ATM | |
| SCHEMBL6990771 | 0.68 | IKBKB (0.51) | IKBKBATRPRKDCMAP2K3ATM | |
| SCHEMBL25810411 | 0.68 | IKBKB (0.48) | IKBKBATRPRKDCMAP2K3ATM | |
| SCHEMBL318797 | 0.67 | ATR (0.68) | IKBKBATRPRKDCATMCYP3A4 | |
| SCHEMBL16837074 | 0.67 | ALDH1A1 (0.51) | MAP2K3LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007050383-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050401-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, RET | IKBKB 576/4885ATR 907/4885PRKDC 83/4885 |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | IKBKB 440/4885ATR 1059/4885PRKDC 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.